Results 261 to 270 of about 318,820 (346)

Motives and predictors of modified Atkins diet discontinuation as treatment of adults with drug‐resistant epilepsy

open access: yesEpilepsia, EarlyView.
Abstract Objective This study was undertaken to explore the motives and predictors of modified Atkins diet (MAD) discontinuation as a treatment of adults with drug‐resistant epilepsy (DRE). Methods A single‐center observational longitudinal study was made of a cohort of patients treated with MAD during the first 6 years at a multidisciplinary ...
Raquel Samões   +6 more
wiley   +1 more source

Long‐term outcomes of stereotactic radiofrequency ablation in hypothalamic hamartomas: A single‐center experience

open access: yesEpilepsia, EarlyView.
Abstract Objective Hypothalamic hamartomas (HHs) lead to refractory epilepsy, and minimally invasive surgical approaches are standard of care for affected patients. Stereotactic radiofrequency thermocoagulation (SRT) is one of the treatment methods recognized to achieve seizure freedom. This study reports surgical outcome from a single center reporting
Peter Christoph Reinacher   +9 more
wiley   +1 more source

Exploration of post-PEG precipitation TSH recovery in hypothyroid patients. [PDF]

open access: yesFront Endocrinol (Lausanne)
Yin J, Mei Z, Zhang B, Tang F.
europepmc   +1 more source

Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study.

open access: yesEuropean Journal of Endocrinology, 2016
M. Søgaard   +5 more
semanticscholar   +1 more source

Serum Visfatin Level and Cardiac Valve Calcifcation in Hemodialysis Patients

open access: yesHemodialysis International, EarlyView.
ABSTRACT Background Cardiac valve calcification is a serious complication in patients with cardiovascular disease. This study investigated the relationship between visfatin levels and cardiac valve calcification in individuals undergoing hemodialysis.
Xiaoqi Wang   +5 more
wiley   +1 more source

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma

open access: yesHepatology Research, EarlyView.
ABSTRACT Background Atezolizumab plus bevacizumab (AB) is a standard first‐line therapy for unresectable hepatocellular carcinoma (HCC). However, data on the efficacy and safety of AB rechallenge (re‐AB) after discontinuation are limited. Methods We conducted a retrospective analysis of 13 patients with unresectable HCC who received initial AB ...
Yuichiro Suzuki   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy